Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GALR2 | O43603 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8953331 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AALDH1A1NPSR1LMNA | |
| SCHEMBL7414257 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2AALDH1A1NPSR1LMNA | |
| SCHEMBL5875056 | 0.85 | KMT2A (0.47) | SMN1; SMN2KMT2AALDH1A1NPSR1LMNA | |
| SCHEMBL2426533 | 0.85 | KDM4E (0.46) | SMN1; SMN2KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL6491502 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2AALDH1A1NPSR1LMNA | |
| SCHEMBL27797779 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL13705663 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2AALDH1A1NPSR1LMNA | |
| SCHEMBL23924910 | 0.80 | KMT2A (0.50) | SMN1; SMN2KMT2AALDH1A1NPSR1LMNA | |
| SCHEMBL15398667 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL27862571 | 0.80 | TSHR (0.50) | SMN1; SMN2KMT2AALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782997-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782997-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1029851-B1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2005-04-20 | — | — | EP | disclosed |
| CN-1145609-C | Piperazine compounds and medical use thereof | ������ҩ��ʽ���� | 2004-04-14 | — | — | CN | disclosed |
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6455528-B1 | TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| CN-1281438-A | Piperazine compounds and their use as pharmaceuticals | EFUKU CO LTD (JP) | 2001-01-24 | — | — | CN | disclosed |
| EP-1029851-A1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | SMN1; SMN2 3736/4885KMT2A 2109/4885ALDH1A1 710/4885 |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | SMN1; SMN2 3777/4885KMT2A 2049/4885ALDH1A1 788/4885 |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | TNF, CCR10, RELA | SMN1; SMN2 3680/4885KMT2A 1815/4885ALDH1A1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.